[06] Session-2: Immuno-Oncology BC -Clinical advances

2021年1月23日(土) 15:00 〜 18:00 ROOM1 (Japan Standard Time)

Start: 15:00(JST) / 7:00(CET) / 0:00(CST)

+全てマイスケジュールに登録

[Z06] Join the ZOOMWebinar [Session2]

Closed.
If you would like to watch the Day1 Lecture,
please go to the page below.
https://confit.atlas.jp/guide/event/kbccc2021/static/Day1Lecture

Introduction (15:00 〜 15:05)

15:05 〜 15:30

[1L11] Absolute Lymphocyte Count is a Predictor of Eribulin Efficacy for Advanced or Metastatic Breast Cancer in EMBRACE and Study 301

*Yasuo Miyoshi¹, Yuta Yoshimura², Kenichi Saito³, Kenzo Muramoto², Kenichi Nomoto³ (1. Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, 2. Eisai Co., Ltd., Koishikawa, Bunkyo-ku, Tokyo, Japan, 3. Eisai Inc., Woodcliff Lake, NJ, USA)

15:30 〜 15:55

[1L12] Novel approaches in the Immuno-Oncology therapy

*Rebecca Dent¹ (1.Head of Medical Oncology and Senior Consultant, National Cancer Centre Singapore)

15:55 〜 16:20

[1L13] Neoadjuvant therapy with Immuno-Oncology agents

*Giuseppe Curigliano¹ (1. European Institute of Oncology, IRCCS and University of Milano, Milano, Italy)

16:20 〜 16:45

[1L14] Antiangiogenesis and PD-1 blockade

*Qiang Liu¹ (1. TBC)

16:45 〜 17:10

[1L15] Alterlation of circulating immune profile in the Immuno-Oncology therapy

*Kosuke Kawaguchi¹ (1. Kyoto University)

Voting and discussion (17:10 〜 18:00)